Duffin, Kevin

A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes

Niewczas, M. A., Pavkov, M. E., Skupien, J., Smiles, A., Md Dom, Z. I., Wilson, J. M., Park, J., Nair, V., Schlafly, A., Saulnier, P.-J., et al. (2019) · Nature Medicine

Chronic Kidney Disease and DiabetesDialysis and Renal Disease Management

Cited by 432

Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: a systematic review and meta-analysis

Selvaraj, E. A., Mózes, F. E., Jayaswal, A. N. A., Zafarmand, M. H., Vali, Y., Lee, J. A., Levick, C. K., Young, L. A. J., Palaniyappan, N., Liu, C.-H., et al. (2021) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentUltrasound Imaging and Elastography

Cited by 376

Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes

Hartman, M. L., Sanyal, A. J., Loomba, R., Wilson, J. M., Nikooienejad, A., Bray, R., Karanikas, C. A., Duffin, K. L., Robins, D. A., & Haupt, A. (2020) · Diabetes Care

Liver Disease Diagnosis and TreatmentDiabetes Treatment and Management

Cited by 351

Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes

Thomas, M. K., Nikooienejad, A., Bray, R., Cui, X., Wilson, J., Duffin, K., Milicevic, Z., Haupt, A., & Robins, D. A. (2021) · The Journal of Clinical Endocrinology & Metabolism

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 345

Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial

Heerspink, H. J. L., Sattar, N., Pavo, I., Haupt, A., Duffin, K. L., Yang, Z., Wiese, R. J., Tuttle, K. R., & Cherney, D. Z. I. (2022) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 306

Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis

Vali, Y., Lee, J., Boursier, J., Spijker, R., Löffler, J., Verheij, J., Brosnan, M. J., Böcskei, Z., Anstee, Q. M., Bossuyt, P. M., et al. (2020) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentLiver Disease and Transplantation

Cited by 302

An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)

Vacca, M., Kamzolas, I., Harder, L. M., Oakley, F., Trautwein, C., Hatting, M., Ross, T., Bernardo, B., Oldenburger, A., Hjuler, S. T., et al. (2024) · Nature Metabolism

Liver Disease Diagnosis and TreatmentDiet, Metabolism, and Disease

Cited by 262

Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study

Vali, Y., Lee, J., Boursier, J., Petta, S., Wonders, K., Tiniakos, D., Bedossa, P., Geier, A., Francque, S., Allison, M., et al. (2023) · The Lancet Gastroenterology & Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 224

Molecular chlorine generated by the myeloperoxidase-hydrogen peroxide-chloride system of phagocytes converts low density lipoprotein cholesterol into a family of chlorinated sterols

Hazen, S. L., Hsu, F. F., Duffin, K., & Heinecke, J. W. (1996) · Journal of Biological Chemistry

Neutrophil, Myeloperoxidase and Oxidative MechanismsAtherosclerosis and Cardiovascular Diseases

Cited by 221

Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis

Mózes, F. E., Lee, J. A., Vali, Y., Alzoubi, O., Staufer, K., Trauner, M., Paternostro, R., Stauber, R. E., Holleboom, A. G., van Dijk, A.-M., et al. (2023) · The Lancet Gastroenterology & Hepatology

Liver Disease Diagnosis and TreatmentLiver Disease and Transplantation

Cited by 214

The dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A p ost hoc analysis

Wilson, J. M., Lin, Y., Luo, M. J., Considine, G., Cox, A. L., Bowsman, L. M., Robins, D. A., Haupt, A., Duffin, K. L., & Ruotolo, G. (2022) · Diabetes Obesity and Metabolism

Diabetes Treatment and ManagementAdipokines, Inflammation, and Metabolic Diseases

Cited by 149

Identification of genetic risk factors in the Chinese population implicates a role of immune system in Alzheimer’s disease pathogenesis

Zhou, X., Chen, Y., Mok, K. Y., Zhao, Q., Chen, K., Chen, Y., Hardy, J., Li, Y., Fu, A. K. Y., Guo, Q., et al. (2018) · Proceedings of the National Academy of Sciences

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 96

Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: A systematic review and meta-analysis

Lee, J., Vali, Y., Boursier, J., Duffin, K., Verheij, J., Brosnan, M. J., Zwinderman, K., Anstee, Q. M., Bossuyt, P. M., & Zafarmand, M. H. (2020) · PLOS ONE

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 74

A sequential algorithm combining ADAPT and liver stiffness can stage metabolic-associated fatty liver disease in hospital-based and primary care patients

Eslam, M., Wong, G. L.-H., Hashem, A. M., Chan, H. L.-Y., Nielsen, M. J., Leeming, D. J., Chan, A. W.-H., Chen, Y., Duffin, K. L., Karsdal, M., et al. (2021) · American Journal of Gastroenterology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 53

Effects of tirzepatide versus insulin glargine on cystatin C-based kidney function: a SURPASS-4 post hoc analysis

Heerspink, H. J. L., Sattar, N., Pavo, I., Haupt, A., Duffin, K. L., Yang, Z., Wiese, R. J., Wilson, J. M., Hemmingway, A., Cherney, D. Z. I., et al. (2023) · Diabetes Care

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 53

Indicators of Kidney Fibrosis in Patients with Type 2 Diabetes and Chronic Kidney Disease Treated with Dulaglutide

Tuttle, K. R., Wilson, J. M., Lin, Y., Qian, H.-R., Genovese, F., Karsdal, M. A., Duffin, K. L., & Botros, F. T. (2023) · American Journal of Nephrology

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 31

Treatment with orforglipron, an oral glucagon-like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes

Wharton, S., Rosenstock, J., Konige, M., Lin, Y., Duffin, K., Wilson, J., Banerjee, H., Pirro, V., Kazda, C., & Mather, K. (2025) · Cardiovascular Diabetology

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 26

The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity

Heerspink, H. J. L., Lu, Z., Du, Y., Duffin, K. L., Coskun, T., Haupt, A., & Hartman, M. L. (2025) · Kidney International Reports

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 23

754-P: Effect of Retatrutide on Kidney Parameters in People with Type 2 Diabetes and/or Obesity—A Post-Hoc Analysis of Two Phase 2 Trials

HEERSPINK, H. L., LU, Z., DU, Y., DUFFIN, K. L., COSKUN, T., HAUPT, A., & HARTMAN, M. L. (2024) · Diabetes

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 7

Abstract 16779: Tirzepatide Reduces High-Sensitivity C-reactive Protein in Patients With Type 2 Diabetes and High Cardiovascular Risk: A Post Hoc Analysis of the SURPASS-4 Trial

Bhatt, D. L., Wilson, J. M., Wiese, R. J., Yang, Z., Duffin, K. L., & Pavo, I. (2023) · Circulation

Diabetes Treatment and ManagementAdipokines, Inflammation, and Metabolic Diseases

Cited by 5